HARP - Harpoon Therapeutics -2.6% proposes public offering

Harpoon Therapeutics (HARP) commences an underwritten public offering of its common stock.Underwriters option to purchase up to an additional 15% of the number of shares sold.Net proceeds of the offering, together with other available funds, to fund the continued clinical development of HPN424 in metastatic castration-resistant prostate cancer, HPN536 in ovarian cancer and other solid tumors, HPN217 in multiple myeloma, and HPN328 for the treatment of small cell lung cancer and other neuroendocrine tumors expressing Delta-like canonical Notch ligand 3; to advance the development of other pipeline candidates, including HPN601; and for working capital and general corporate purposes.

For further details see:

Harpoon Therapeutics -2.6%, proposes public offering